BioCardia’s Helix transendocardial delivery system is the leading percutaneous catheter delivery system for cardiovascular regenerative medicine. It enables local delivery of cell and gene based therapies to treat heart failure, myocardial infarction, ischemia, and cardiac conduction disorders.
The Helix catheter's small hollow, distal helical needle is advanced from a blood vessel in the groin similar to an angioplasty catheter, over the aortic arch and across the aortic valve through the FDA-cleared Morph guide catheter. The Helix is then advanced from the Morph, and its helical needle is rotated into the heart tissue to provide active fixation during therapeutic delivery, similar to the active fixation electrodes used in cardiac pacing. This fixation to the beating heart wall provides for stability and control during the delivery procedure. It uses simplified fluoroscopic imaging, crosses the aortic arch and valve over a guide wire, and provides the operator with three degrees of freedom to maximize operator control. Leading physicians have described the current Helix system as elegant in its simplicity.
The Helix catheter is under investigational use in the United States and CE Mark received for the European Union.
CAUTION. CardiAMP Therapy, CardiALLO Therapy, and Helix device are investigational. Limited by United States Law to Investigational Use. BioCardia®, CardiAMP™, CardiALLO™, Helix™, and Morph® are trademarks of BioCardia, Inc. This site is protected by United States and international copyright and trademark laws. The contents of the Site may not be distributed, modified, reproduced, or used, in whole or in part, without the prior written consent of BioCardia. Any copies of material or other content provided through the Site must include the same copyright and other proprietary notices that appear with the material or content.